Vitaccess

We've been focused on the patient's voice since we were founded in 2017. Our white paper, co-authored with Thomas Smith, discusses how gaining a deep understanding of patients’ lived experiences equips researchers, healthcare providers, and manufacturers with better information with which to make decisions and developments that enhance patient outcomes. Read it here: https://hubs.ly/Q02KybsG0 #patientcenteredresearch #patientengagement

If you missed our webinar, “What is the point of real-world evidence?”, you can watch it on demand on our website: https://hubs.ly/Q02KydYk0 Mark Larkin PhD and Akosua Ofori were joined by RWE expert, Jeff Trotter, to discuss why real-world evidence is increasingly being used in the healthcare industry. #keepingitreal #webinar #realworldevidence

We are experts in understanding, measuring, and articulating patient experience in the real world. See our brief "Challenge, Solution, Value" case studies for some examples: https://hubs.ly/Q02Kyfs20 #patientcenteredstudies #PCO

Anna Richards and Sam Llewellyn recently visited Boston to meet with our clients about exciting upcoming research - and shared some lovely pictures on their return!

Check out this recent publication exploring the psychometric properties of MG-ADL items and the MG-ADL score in myasthenia gravis (MG), which includes data from the MyRealWorld MG dataset: https://hubs.ly/Q02LxN_d0 Vitaccess is the steward of the MyRealWorld MG dataset, which is available for industry-led and academic research. If you are interested in learning more MyRealWorld MG or exploring options for access to data from over 2,000 MG patients, visit our website: https://hubs.ly/Q02LxPbn0

This month, we've got the spotlight on Spinal Muscular Atrophy (SMA). Did you know that the symptomatic management of SMA includes - but is not limited to - physical therapy, occupational therapy, respiratory function monitoring, and nutritional status monitoring? Did you know that the first of three disease-modifying therapies currently approved by the FDA for SMA was approved in 2016? The burden of SMA can be significant, and research is ongoing to develop new treatments to improve symptoms and quality of life. Real-world data can be invaluable in demonstrating burden of illness and efficacy of existing and novel treatments. To find out how Vitaccess can support you in generating fit-for-purpose real-world evidence in SMA and other rare conditions, get in touch today at https://bit.ly/3AcuIkt

Sam Llewellyn, Associate Director, Patient-Centered Outcomes, and Octavia Borecka, PhD, Senior Research Associate, recently co-authored a publication titled "Real world effectiveness of guaifenesin ER in tackling mucus hypersecretion in stable chronic bronchitis". Check it out here: https://bit.ly/3AdRd8r For more Vitaccess publications, visit: https://bit.ly/3YxQMji

This Spinal Muscular Atrophy (SMA) awareness month, we are looking at the value of real-world evidence in demonstrating the safety and efficacy of therapies in the post-marketing environment. This 2024 publication by Gowda and colleagues describes the real-world use and impact of onasemnogene abeparvovec (Zolgensma) in 99 pediatric patients with SMA type 1: https://hubs.ly/Q02FNWWc0 At Vitaccess, we support our clients to meet their real-world evidence generation needs, pre- to post-marketing. To learn more, schedule a capabilities call with Anna Richards, Head of Commercial: https://hubs.ly/Q02FNWSq0

Sally-Anne Vincent, Senior Consultant at Vitaccess will be moderating a panel on the accuracy of existing measurement tools in assessing health-related quality of life of informal caregivers at this year's ISPOR EU! Join Sally and the panellists - Alice Biggane, Fleur Chandler, and Jill Carlton - this November. https://bit.ly/46IhaJt

We are delighted to announce the launch of The Vitaccess Real MG Registry, a new patient-centric, tech forward registry designed to capture longitudinal observational data on myasthenia gravis, its treatment, and impact on symptoms, daily activities, and quality of life. The registry will link direct patient-reported data with data reported by healthcare professionals and from patients’ existing medical records. Adult patients with MG will be recruited to the registry in a number of ways. If you are interested in learning more about the registry – including whether you can be involved as a patient participant or as a neurologist treating MG patients in the community – please visit the registry’s informational site: https://bit.ly/3JM48A5. To speak with a member of our team, contact us at https://bit.ly/3QsH7G3.